

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/717,088

Please add the following new claims:

-- Claim 22. A non-aerosol sprayable skin patch composition
B1 consisting essentially of;

- (a) ~~0.01% to 10%~~ w/w of at least one water-soluble physiologically active ingredient;
- (b) 1% to 50% w/w of at least one substantially water insoluble film forming agent selected from the group consisting of acrylic acid, polyacrylic acid, polybutylmethacrylate, polymethacrylic acid, ascorbyl palmitate, carbomer, cellulose acetate phthalate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, hydroxypropyl methylcellulose phthalate, hypomellose phthalate, crospovidone, cetyl alcohol, poloaxmer, polyethylene glycol, polyvinyl acetate, polyvinyl acetate phthalate, polyvinyl alcohol, and povidone;
- (c) 0.1% to 20% w/w of at least one film plasticiser agent; and
- (d) 30% to 90% w/w of at least one volatile organic solvent,

wherein said composition forms a flexible, porous and physiologically compatible skin patch when sprayed onto skin and is allowed to dry, wherein said patch disintegrates progressively over a 24-48 hour time period.

Claim 23. The composition according to Claim 22, wherein said at least one physiologically active ingredient is an antimicrobial agent and/or an antifungal agent.

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/717,088

Claim 24. The composition according to Claim 23, wherein said antimicrobial agent is a quaternary ammonium compound.

BL
Ent
Claim 25. The composition according to Claim 24, wherein said quaternary ammonium compound is selected from the group consisting of cetrimide, alkylaryltrialkylammonium chloride, alkylaryltrimethylammonium chloride, amantanium bromide, benzalkonium chloride, benzethonium chloride, benzododecinium bromide, cetalkonium chloride, cethexonium bromide, centrimum bromine, and cetyldimethylethylammonium bromide.

Claim 26. The composition according to Claim 25, wherein said quaternary ammonium compound is cetrimide.

Claim 27. The composition according to Claim 23, wherein said water-soluble compound is a mixture of a water-soluble antimicrobial agent and a water-soluble antifungal agent.

Claim 28. The compound according to Claim 27, wherein said antimicrobial agent is a quaternary ammonium compound and said antifungal agent is selected from the group consisting of chlorbutanol, phenol, salicylic acids, arisoran, amoralfine, amphotericin, bifonazole, butoconazole nitrate, chlormidazole, clotrimazole, croconazole, econazole, enilconazole, fenticonazole, fluconazole, flutrimazole, isoconazole, itraconazole, ketoconazole, lanoconazole, miconazole, omoconazole, saperconazole, sertaconazole, sulconazole, terconazole, tioconazole, benzoyl disulphide, bromochlorosalicylanilide, buclosamide, butenafine, candicidicaprylic acid, chlorphenesin, ciclopirox olamine, cilofungin, fenticlor, flucytosine, criseofulvin, hachimycin, haloprogin, hamycin, hydroxystilbamidine, isethionate, loflucarban, mepartricin,

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/717,088

natamycin, nifuroxime, p-nitrophenol, nystatin, pentamycin, propionic acid, protiofate, pyrrolnitrin, sulbentine, terbinafine, tolclate, tolnaftate, triacetin, and undecenoic acid.

B1
cont Claim 29. The compound according to Claim 28, wherein said antifungal agent is chlorbutanol.

Claim 30. The composition according to Claim 22, wherein said at least one physiologically active ingredient is selected from the group consisting of an antiseptic, an antiparasitic, a nicotine, a cortico steroid, a pain relieving agent, a cardiac dilater, a cardiac stimulant, an antihistamine, an anti-inflammatory, an anti blood clotting agent, a growth hormone, a sex hormone, a drug commonly used for diseases in the alimentary system, central nervous system, musculoskeletal system, genitourinary system allergy or immune system, and a biologically active peptide or protein.

Claim 31. The composition according to Claim 30, wherein said at least one physiologically active ingredient is triclosan.

Claim 32. The composition according to Claim 22, wherein the film forming agent is selected from the group consisting of polymethacrylic acid, polybutyl methacrylate and polyacrylic acid.

Claim 33. The composition according to Claim 22, wherein said film plasticiser agent is polybutylphthalate.

Claim 34. The composition according to Claim 22, wherein said organic solvent is selected from the group consisting of isopropanol, acetone and ethylacetate.

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/717,088

Claim 35. A non-aerosol sprayable skin patch composition consisting essentially of:

- B1
Cmt
- (a) 0.01% to 10% w/w of at least one water-soluble physiologically active ingredient;
 - (b) 1% to 50% w/w of polymethacrylic acid;
 - (c) 0.1% to 20% w/w of polybutylphthalate;
 - (d) 0% to 90% w/w of isopropanol;
 - (e) 0% to 90% w/w of acetone; and
 - (f) ethylacetate up to 100% w/w,

wherein said composition forms a flexible, porous and physiologically compatible skin patch when sprayed onto skin and is allowed to dry, and wherein said patch disintegrates progressively over a 24-48 hour time period.

Claim 36. The composition according to Claim 35, consisting essentially of:

- (a) 0.05% w/w of cetrimide,
- (b) 0.07% w/w of triclosan,
- (c) 0.6% w/w of chlorbutanol,
- (d) 10% w/w of polymethacrylic acid,
- (e) 1.2% w/w of polybutylphthalate,
- (f) 4% w/w of isopropanol,
- (g) 24% w/w of acetone, and
- (h) ethylacetate up to 100% w/w.

Claim 37. A method of improving wound healing or administering a physiologically active ingredient to a patient comprising spraying on to a wound or on to skin of a patient in need thereof, an effective amount of a composition according to Claim 22.